Viberzi (eluxadoline) treatment for irritable bowel syndrome with diarrhea is now launched in the US- Allergan
Allergan plc , has announced that Viberzi (eluxadoline), the company's first-in-class treatment for irritable bowel syndrome with diarrhea (IBS-D), is now available by prescription in the U.S.
On November 12, 2015, the Drug Enforcement Agency (DEA) completed its review of Viberzi (eluxadoline), and published its Final Rule placing Viberzi into Schedule IV of the Controlled Substance Act. Schedule IV drugs, substances, or chemicals are defined by the DEA as drugs with a low potential for abuse and low risk of dependence.
Comment:Ironwood Pharmaceuticals, Inc.will co promote Viberzi (eluxadoline), Allergan’s new treatment for adults suffering from irritable bowel syndrome with diarrhea (IBS-D). This arrangement is separate from and complementary to the companies’ ongoing co-development and co-commercialization of Linzess (linaclotide) for the treatment of adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins